Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3
Status:
Recruiting
Trial end date:
2023-11-20
Target enrollment:
Participant gender:
Summary
Protocol Title: DOLCE: Dolutegravir-Lamivudine for naïve HIV-Infected Patients with ≤200
CD4/mm3
Protocol Number: FH-57
Study Objectives: To assess the antiviral activity at week 48 of DTG+3TC among naïve HIV
patients with a CD4 count ≤200 cells /mm3.